Claims
- 1. A composition comprising of a monomer component comprised of at least one alkyl cyanoacrylate and at least one inhibitor, and a second component comprised of a resultant aggregate structure formed from an alkyl cyanoacrylate monomer, an alkyl esterified fatty acid and an opacificant agent where said composition forms a resultant aggregate structure when said composition contacts an anionic environment.
- 2. The composition of claim 1, wherein said monomer component is comprised of one alkyl cyanoacrylate and at least one inhibitor.
- 3. The composition of claim 2, wherein said alkyl cyanoacrylate is 2-hexyl cyanoacrylate.
- 4. The composition of claim 3, wherein said monomer component has at least two inhibitors.
- 5. The composition of claim 3, wherein said monomer component has at least three inhibitors.
- 6. The composition of claim 5, wherein one inhibitor is hydroquinone.
- 7. The composition of claim 6 wherein hydroquinone is in the range of about 50 to 150 parts per million.
- 8. The composition of claim 5, wherein one inhibitor is p-methoxyphenol.
- 9. The composition of claim 8, wherein p-methoxyphenol is in the range of about 50 to 150 PPM.
- 10. The composition of claim 5, wherein one inhibitor is phosphoric acid.
- 11. The composition of claim 10, wherein phosphoric acid is in the range of about 125 to 375 PPM.
- 12. The composition of claim 6, wherein hydroquinone is in the range of about of about 50 to 150 parts per million.
- 13. The composition of claim 8, wherein p-methoxyphenol is in the range of about 75 to 125 PPM.
- 14. The composition of claim 10, wherein phosphoric acid is in the range of about 187.5 to 312.5 PPM.
- 15. The composition of claim 6, wherein hydroquinone is in the range of about 95 to 105 PPM.
- 16. The composition of claim 8, wherein p-methoxyphenol is in the range of about 95 to 105 PPM.
- 17. The composition of claim 10, wherein phosphoric acid is in the range of about 200 to 300 PPM.
- 18. The composition of claim 5, wherein said three inhibitors are hydroquinone, p-methoxyphenol and phosphoric acid.
- 19. The composition of claim 3, wherein said resultant aggregate structure is formed from 2-hexyl cyanoacrylate.
- 20. The composition of claim 19, wherein said alkyl esterified fatty acid is selected from the group consisting of alkyl laurate, alkyl palmitate and stearic alkyl myristate.
- 21. The composition of claim 20, wherein said alkyl esterified fatty acid is ethyl myristate.
- 22. The composition of claim 19, wherein said opacificant agent is selected from group consisting of gold, platinum, tantalum, titanium, tungsten and barium sulfate.
- 23. The composition of claim 22, wherein said opacificant agent is gold.
- 24. The composition of claim 22, wherein said gold is in fine powder form with individual particles no larger than about 7 microns in diameter.
- 25. The composition of claim 22, wherein said gold is in fine powder form with individual particles no larger than about 5 microns in diameter.
- 26. The composition of claim 22, wherein said gold is in fine powder form with individual particles no larger than about 2 microns in diameter.
- 27. The composition of claim 22, wherein said gold is in fine powder form with individual particles no larger than about 1 micron in diameter.
- 28. A composition comprising of a monomer component comprised of 2-hexyl cyanoacrylate and hydroquinone, p-methoxyphenol and phosphoric acid, and a second component comprised of a resultant aggregate structure formed from 2-hexyl cyanoacrylate, ethyl myristate and gold, where said composition forms a resultant aggregate structure when said composition contacts an anionic environment.
- 29. A composition comprising of a monomer component comprised of an alkyl cyanoacrylate, at least one inhibitor and a second component that functions as a opacificant agent and polymerization retardant where said composition forms a resultant aggregate structure when said composition contacts an anionic environment.
- 30. The composition of claim 28, wherein said second component is a halogenated oil.
- 31. The composition of claim 28 wherein, said second component is Ethiodol.
- 32. A composition comprising of a monomer component comprised of 2-hexyl cyanoacrylate and hydroquinone, p-methoxyphenol and phosphoric acid, and Ethiodol.
- 33. A method of filling, occluding, partially filling or partially occluding an unfilled volume or space in a mass in an anionic environment comprising administering a composition of claim 1.
- 34. The method of claim 33, wherein said space is an existing space in the body.
- 35. The method of claim 33, wherein said space is created by a transiently placed external device.
- 36. The method of claim 33, wherein said space is created or resulting from a procedure.
- 37. The method of claim 33, wherein said space is created by the placement or implantation of an object.
- 38. The method of claim 33, wherein said space is created by the composition itself.
- 39. The method of claim 34, wherein said existing space is a lumen of a passageway in the body.
- 40. The method of claim 34, wherein said existing space is a blood vessel
- 41. The method of claim 34, wherein said existing space is a duct.
- 42. A method of ablating diseased or undesired tissue by cutting off the blood supply to said tissue, comprising administering a composition of claim 1 to the blood vessel(s) that feed said tissue, where said blood vessel(s) are occluded thereby cutting off the blood supply to said tissue.
- 43. The method of claim 42, wherein said undesired tissue is an arteriovenous venous malformation.
- 44. The method of claim 43, wherein said undesired tissue is a tumor.
- 45. The method of claim 43, wherein said undesired tissue is an uterine leiomyoma.
- 46. A method of treating arteriovenous venous malformation (“AVM”) comprising administering a composition of claim 1 to the blood vessel(s) that feed said AVM, where said blood vessel(s) are occluded thereby cutting off the blood supply to said AVM.
- 47. A method of treating a tumor comprising administering a composition of claim 1 to the blood vessel(s) that feed said tumor, where said blood vessel(s) are occluded thereby cutting off the blood supply to said tumor.
- 48. A method of treating an uterine leiomyoma comprising administering a composition of claim 1 to the blood vessel(s) that feed said uterine leiomyomas, where said blood vessel(s) are occluded thereby cutting off the blood supply to said uterine leiomyoma.
- 49. A method of sterilizing a female mammal comprising administering a composition of claim 1 to the fallopian tubes thereby preventing the passage of the eggs from the ovaries to the uterus of said female mammal.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. Ser. No.: 09/241,368, filed Jan. 29, 1999, which is incorporated herein by reference.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09241368 |
Jan 1999 |
US |
Child |
09497075 |
Feb 2000 |
US |